New variant may force drug companies to tweak Covid vaccination plans

The emergence of the Omicron strain could lead drug companies scrambling to the drawing board to tweak their Covid-19 vaccine plans. US firm Novavax and Russia’s Gamaleya Institute said on Monday that they had initiated work on developing new versions of their respective vaccines adapted to the mutant strain. Pfizer and Moderna too said they were racing to tweak their vaccines.